Loxo chief Josh Bilenker steps in (temporarily) to head oncology R&D at Eli Lilly as Levi Garraway steps out

John Carroll

Editor & Founder

Josh Bilenker didn’t just gain a personal windfall by selling Loxo to Eli Lilly for $8.1 billion. He got a new, if temporary, job out of the deal as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Loxo chief Josh Bilenker steps in (temporarily) to head oncology R&D at Eli Lilly as Levi Garraway steps out

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

GSK accuses Pfizer and BioNTech of mRNA patent infringement

Updated: Bristol Myers plans $1.5B in cost cuts, including 2,200 jobs, as CEO promises more ‘agile’ company

Sage focuses on successful launch of postpartum depression drug

Bristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks

In rare move, Colombia issues compulsory license for HIV medicine in effort to expand access

Despite oncology cutbacks, Sanofi isn’t out of the game yet with early assets

Loxo chief Josh Bilenker steps in (tem­porar­i­ly) to head on­col­o­gy R&D at Eli Lil­ly as Levi Gar­raway steps out

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

more like this

Benchling

San Francisco, CA, USA

Loxo chief Josh Bilenker steps in (temporarily) to head oncology R&D at Eli Lilly as Levi Garraway steps out